Introduction
Despite major advances in the prediction, detection and management of cardiovascular disorders during the past 40 years, cardiac arrest and sudden cardiac death (SCD) remains a major worldwide public health problem. 1 The 40% reduction in age-adjusted cardiovascular mortality between 1990 and 2008 2 does not appear to have had the same impact on cumulative numbers and proportional contributions of cardiac arrest and SCD. 3 Current estimates of the SCD burden remain in the range of 45 to 50% of all cardiovascular deaths, 4 accounting for 424,000 nontraumatic out-of-hospital cardiac arrests (OHCA) responded to by emergency rescue systems annually, with a mortality rate of approximately 90 percent, 5 accounting for the estimated 300,000-382,000 SCD's per year in the U.S. 4 This is ten times the annual mortality rate for breast cancer, and equivalent to the annual mortality rates for Alzheimer's disease, breast cancer, cervical cancer, colorectal cancer, diabetes, HIV/AIDS, prostate cancer, as well as death from guns, residential fires, car accidents, and suicide combined. 2, 4, 6 Moreover, individual risk prediction continues as an unresolved challenge that is the rate-limiting step for progress in clinical practice.
It is unlikely that major impact on individual risk prediction will emerge from anything short of large-scale research efforts to identify small subgroups at very high risk that are currently concealed within larger general population subsets at low cumulative risk. This analysis is designed to summarize the epidemiological and clinical factors that limit prediction and prevention of SCD, develop the rationale for a new approach to research funding, and propose a different resource for such funding.
Analysis of the Problem
The first principle for defining the SCD challenge derives from its complex epidemiology. The erge g ncy y rescue sys ys s ste te te tem m ng for or t t the he h h e e t t st sti i im imat at ted ed ed ed 4 This s s s i i i is ten times th he an n n nn nu n n al mortality rate for ce e e er, and equiva ale ent to o the he he ann nua u l m morta t tality y r rates e es f f and preserved cardiac function, (4) the class of patients with known heart disease and poor heart function, and (5) a category associated with confirmed or suspected genetic abnormalities associated with cause or risk of SCD. 7 The category referred to as the general population literally represents the total population, but by usage has become conceptualized as a large population, excluding the other 4 subsets identified by their specific risk characteristics. Available statistics suggest that the cumulative number of SCDs emerging from the 4 specific categories is a small fraction of those occurring in the general population, the latter being dominated by subjects without identified cardiovascular disease or high impact risk markers. Therefore, for the purpose of research planning and development of preventive strategies, it is logical to consider the general population category as those individuals at unrecognized risk for cardiac arrest, often expressing as the first clinical manifestation of previously undiagnosed or unsuspected heart disease.
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In the second category, characterized by the presence of risk factors for development of disease, SCD risk is considerably higher than the segment of the population without risk markers, but still low enough to create a challenge for accurately predicting and preventing SCD in the individual subject. The risk factors in this category are used in various scoring systems and other clinical risk profiling strategies. The major risk factors, including diabetes, cigarette smoking, obesity, hypertension, obesity, diet, and sedentary life style, associate with increased resen nts ts t t t t the h h he to t t tota t t tal l l l p pop op op opu u ge has become conceptualized as a large population, excluding the other 4 subset by their specific risk characteristics. Available statistics suggest that the cumulat by y y y t t th t eir specif fic ic ris s sk k k char ar aracte eri ri rist t tic cs. A A Avai ila abl l le e e st st st s a a at a i isti i ics s sug gg ges s st that t t th h he c cum mu mul l lat SCDs Ds Ds Ds e e em m m merg rgin i i i g fr f f om the 4 4 4 4 speci i i ifi fi fi fic c c ca c catego go i i ri ies s s i i i is a a a s s sm smal al al ll l l f f f fra t t t ction of of of f t those occurr l po p p pu p p l la l ti i ion, th th th he l l la l tter be b b i in i g g g do i i minat ted by by by subj bj bject ts wit i itho ho ho h ut id id id identi i ifi fi fi fi d ed d card rd rd rdio io io i v v va v sc hi hi h gh i i t t i ri k sk k ke T Th he f fo f fo th th f of h h l pl i ni d nd risk in this population subset based on the number of risk factors, and risk factor interventions offer benefit from a population perspective. However, individual effect size and prediction remain a challenge that should be a target of future research. The importance of identification within this subgroup is further highlighted by a recent observation that out-of-hospital cardiac arrest victims who are admitted to a hospital alive are increasingly likely to have only risk factors, as opposed to manifest disease. 8 The complexity within both of these first two categories is that the number and power of the specific risk factors available for either groups or individuals establish gradients of risk, based on the sizes of the denominators and event rates
( Figure 1 ).
The third and fourth categories are those recognized in clinical practice, in which risk profiling has become dependent upon imperfect sets of clinical markers that have evolved over years. The final category, genetic determinants of risk, include both rare arrhythmia syndromes and the recognized familial risk of cardiac arrest as the initial manifestation of heart disease in the general population. 1 Rare inherited arrhythmias constitute a category that stands alone as a specific component, while familial clustering of SCD risk offers the potential to contribute to risk profiling in the general population and categories of common causes of SCD.
Each of the defined categories of risk has unique epidemiologic characteristics and clinical challenges, requiring different approaches to the translation of population risk to individual risk and interventional strategies. The relevant epidemiological targets are subclassified into conventional epidemiology, transient risk prediction, interventional epidemiology, and genetic/personalized risk prediction. Conventional epidemiology is best applied to the general population at risk for SCD as a first cardiac event in the absence of recognized structural heart disease. The concept of the epidemiology of transient risk refers to a strategy for minators and event t ra ra ra rate t Genetic epidemiology refers to personalized risk identified at a molecular level.
The various categories of population risk require further analysis in the context of the pathophysiology of cardiac arrest itself. These include substrate-based risk derived from underlying structural disease analysis, and expression-based risk derived from factors that have the potential to convert a stable substrate into an active arrhythmogenic substrate. 9 Substrate and expression risks intersect within the various epidemiologic strategies discussed above.
Expression factors include neurohumoral contributions to electrophysiological instability, hemodynamic variants contributing to cardiac arrest risk, markers of electrophysiologic instability, and the role of genetic variants in each of these pathophysiological subsets.
Rationale for Seeking a New Approach to Funding
It is evident from the forgoing that the challenge of SCD prediction and prevention is a a a al t t to t convert a a s stab b ble e sub ub ub bs s strate t t te int n nto an n activ ive ar a arrh rh rhyt yt yt y hm hm mo o ogen nic c sub ub ub u stra ate te te t . n factors in i i cl l lud ud ud de neur h oh humoral l l l contr t ib ib ibuti i ions t to l l el lectrop op op phy hy hy h sio io io ol l lo l gi gi gical l l l in i i st tab ab ab abil il il i it it it ity, y, y i mi i ri t ts t trib ib t ti in t to d rdi ia t st i isk k k rk f of l el t tr h h i si l ol i ic larger cluster of events that are diluted in much larger population denominators, creating lower population risk, but large cumulative numbers. Identification of small pockets of high-risk density within large population subsets offers the best opportunity for the reduction of the SCD burden, but constitutes the greatest challenge ( Figure 1 ). The research models will differ for the first event subgroup, those with risk factors in the absence of defined disease, and those with defined disease with preserved cardiac function. In part, these are currently addressed as general preventive strategies in an attempt to achieve a population effect that is desirable and necessary, but not sufficient to have a major impact alone. Additional studies are needed to identify pathways of investigative efforts that will yield high-resolution risk profiling to identify targets of opportunity for individual risk prediction. Such studies will be complex and expensive. 9, 11 They will also require designs that are much longer than conventional studies to yield meaningful outcome data. However, when dealing with a condition that accounts for one-half of all cardiovascular deaths, with half of those emerging as the first manifestation of previously substantially to the nationwide research commitment, accounting for more than 50% of the $110 billion U.S. biomedical research budget, 14 while the NIH budget has recently remained constant in the range of $30 billion. However, in contrast to the past, the vast majority of industry support is currently allocated for product development and testing, and meeting regulatory requirements.
Very little goes to the type of preclinical research that would improve pathophysiological pathway identification and population science for improved risk prediction, endeavors where the promises for future efficiencies are hidden.
On the surface, hope for substantial increases in the type of support proposed appears dismal. But perhaps we have remained too focused on the notion that funding of biomedical research should be restricted to public and private sources with a primary research mission. If society has so much to gain, and conventional sources of funding have blunted, other elements should be considered in the funding mix.
Potential Impact of Research Investment by the Insurance Industry
Prior suggestions for expanding the research funding base have included establishment of taxadvantaged biomedical innovation trusts, preferential funding for new research institutes, creation of a new class of bonds dedicated to support discovery, and deferring patent protection to later in the discovery chain in return for funding. 15 Another example, given only limited consideration, are the insurance industryies (health, disability, and life), which might have much to gain from improvements in prediction, prevention, and therapeutic efficiencies. The issues and opportunities can be considered individually for each component.
Health Insurance
The health insurance industry has multiple levels of exposure directly associated with cardiac arrest and SCD. Costs are generated for both OHCA and in-hospital cardiac arrest (IHCA) p ppo p rt p propo p sed ap appe pe pe pea a fundi di di ding ng o of f f f bi bi bi biom omed ed ed edic ic ic ica hould be restricted to public and private sources with a primary research mission. Finally, insurers bear the cost of long-term strategies for prevention of SCD, primarily ICD's, in population subsets at high risk for cardiac arrest. The latter include both SCD preventive therapy targeted to survivors of cardiac arrest (secondary prevention) and prevention of SCD within high-risk subgroups, based on risk profiling (primary prevention). 16 Hospital costs for OHCA victims who are resuscitated and arrive at hospital alive are substantial. A recent meta-analysis of 140,000 individuals who experienced out-of-hospital cardiac arrests, found that the survival rate to hospital admission was 23.8% and the survival rate to hospital discharge was 7.8%. 17 Applying these rates to the estimated numbers of Emergency
Rescue cardiac arrest runs annually, 5 yields an estimated 100,912 hospital admissions per year, with 33,072 patients discharged alive and 67,840 dying in-hospital. In another study, the direct incident-related cost of providing care to a patient experiencing an OHCA was estimated to be $102,017, 18 including acute care and early rehabilitation. Allocating proportional costs from the meta-analysis data to differences between survivors to discharge and those who died during hospitalization generates an annualized cost of $2.8 billion, based on the estimate of post-OHCA hospitalizations. 5 An additional $3.01 billion is allocated to care in long-term facilities and $800 million is expended for initial ICD implants in OHCA survivors, assuming 80% of survivors patients discharged alive and 67,840 dying in-hospital. In another study, the d lated cost of pro iding care to a patient e periencing an OHCA as estimated to est t t ts, s, s, s f f f fou o ound nd nd nd tha a at t t t the survival rate to hospi i i ita ta tal l admission wa w w s 2 23 2 2 .8% and the surviv d d di d s s sc s harge was s 7 7.8% % %. 17 17 17 17 A App pl l ly l in n ng g th hese ra rat tes to to to o t t t the h he h e est t tima ate ed n n nu umbe be e er rs r o of f Em m me e erg rdiac a a a arr rr rre es es est runs annually, y The other major cost center for insurers is that related to implantable device therapy for patients determined to be at high risk for a primary cardiac arrest, with or without heart failure, Private insurance providers serving in commercial markets would be major beneficiaries of a reduction in health care costs allocated to short-and long-term OHCA and IHCA survivors, and better efficiencies in primary prevention strategies, helping the industry to remain viable in a w-up p and monitoring ng ng ng c e exp pen endi di di dit tu tu t re res s re r la la la late te te ted d All have an interest in cost savings. The return on investment from a reduction in the incidence of cardiac arrest and its consequences would be significant.
When analyzing cost figures, especially for expensive long-term interventions, it is important to recognize that the health care insurers inherit the limitations of our ability as investigators and physicians to identify individuals or small subgroups at high risk, and to prescribe expensive therapies efficiently. These limitations result from marginal research funding patterns for past pivotal clinical trials that were usually sufficient to adequately define acceptable levels of efficacy, but not optimal. Most were underpowered for stratification of individual risk efficiently. 16, 24, 25 The latter is generally viewed as a metric of the proportion of a treated population that will achieve the targeted benefit -either absolute risk reduction (usually a small number) or the number needed to treat to prevent one event (often a relatively large number).
Accordingly, one could make an argument that health care insurers, including both private carriers and CMS, should have an incentive to contribute to such research efforts. The rationale, while inclusive of good will and general welfare, can be based on business modeling alone. To the extent that investment in a higher level of individual risk prediction would lead to greater efficiencies in the expenditures of health care funds, the insurance system would achieve improvements in its business model. An example is reduced ICD expenditures based upon improved individual risk prediction. In this example, our limitation in the ability to risk profile m interventions, it it t t i i i is s ons o of f f f ou our r ab ab b bil il il ilit it it ity y y as as as as xpensive therapies efficiently. These limitations result from mar nal research fu r past pivotal clinical trials that were usually sufficient to adequately define acce fficacy, but not optimal. Most were underpowered for stratification of individual 16, 24, 25 The latter is generall ie ed as a metric of the proportion of a treated 
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Disability Insurance
To the extent that currently available responses to OHCA are successful, a population of survivors are created, a significant proportion of whom have long-term neurological disabilities. There is an added component to the disability model that affects employees, as well as the costs of disability that are passed on to the employer. It is estimated that an employer incurs a cost 1.75 times the earnings of the affected worker, related to the cost of replacing the individual.
There are an estimated 39,000 to 48,750 individuals who die in the workplace from cardiac arrest. 5, 28 The psychic impact on survivors in the workplace and the net impact on surviving workers performance is significant.
Life Insurance
There would appear to be a business advantage for delaying deaths for life insurance policy holders, allowing companies to earn off of retained funds for longer periods of time. Although the same advantage might not hold for their expanding annuity businesses, it is notable that the life insurance industry did create a Life Insurance Medical Research Fund in 1945. 29 The fund provided support primarily for the generic type of science envisioned here, plus training grants, and structured the program as a foundation, led independently by prominent clinical scientists.
The research fund appears to have ceased functioning in the early 1990's. So the concept is not new, but is worthy of re-exploration in light of current funding dilemmas.
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disincentive to insurers to issue policies to individuals populating the newly-identified high-risk subgroups. Whereas a person cannot be denied health care insurance under the ACA, nor can they be charged a higher premium for higher risk, there is no such requirement placed on life insurance companies. This disincentive argument is countered, however, by the parallel goal of early interventions for preventing premature deaths once such subgroups are identified, providing a net benefit to the insurer and the general population. Reducing first-event SCDs from 50% to 20% by effective routine risk profiling earlier in life could provide a broad-based societal benefit, encompassing the realms of health care cost efficiency, disability payments to cardiac arrest survivors with neurological deficits, and premature life insurance payouts, while also preventing the annual unanticipated premature loss of some proportion of up to 150,000
people, many still in their productive years.
Revisiting the Pharmaceutical, Biotechnology and Medical Device Industries
In addition to the insurance industries, the pharmaceutical, biotechnology and medical device industries may also gain from returning to contributions for research beyond the scope of direct product development. Extending the example of ICDs cited earlier, implants appear to be decreasing based upon effective interventions for acute coronary syndromes and other therapies.
If they were to decrease further for the common Guidelines-based indications as a result of better risk profiling, the device business would be further reduced -an apparent disincentive.
However, this loss might be offset by new indications emerging in parallel by developing insights into pockets of high risk in the general population that currently contribute such large numbers to first-event SCDs. The dilemma of a low incidence concealed in a large denominator
translates to large numbers that may identified within subgroups of high risk density (Figure 1 ). 9 The net effect over time can be positive for both the corporations and the public.
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Interface between Business Interests, Cost Effectiveness, and Clinical Benefits
The interface requires a model that would be acceptable to the various segments of the insurance industries, investigators and universities, government, and the public. The previously suggested creation of research trusts 14 is a good starting point, but does not mention sources of funding, independent of tax benefits. The term "set-asides," mentioned previously in this statement cannot take the form of a federal tax on industry for support of expanding research; that does not appear feasible in this era. In contrast, if the industries see business merit to the concept, a direct infusion into carefully structured, tax-advantaged independent entities, dedicated to prediction and prevention research, would likely be the most palatable funding and management mechanism.
To preserve credibility and be compliant with the law, such entities would have to be carefully structured for independence, oversight, and transparency, as discussed elsewhere. 30 For example, in addition to a charter defining intent and organization, the trusts might consider creating institutes, having an Executive Committee for policy oversight and adherence, and one or more Research Evaluation Committees (study sections), with final decisions recommended by an Awards Committee.
In contrast to a recent study supporting the long-held view that public research funding contributes to the general economy beyond the confines of academic research institutions, 31 the arguments provided here are largely developed from the perspective of a combination of private and public business considerations and the potential for public health benefits. Given that the costs of cardiac arrest to the insurance industry are so large, and significantly outstrip the death rate and associated costs of so many other health and insured events, it is curious that research is not supported significantly in the health insurance sector. In other sectors of the insurance It is unrealistic to expect the contributions of a few corporations to fund the development of a product that by its nature would trickle into the public domain and benefit all, even if it were taxadvantaged. 14 Contributions proportionate to corporate size or market share might be principles for compromise. But, as stated above, there is a strong precedent for insurance company consortiums to support research in other sectors of the economy.
Finally, setting the business element aside, and thinking of the parallel public health and medical practice gains, the initiatives proposed offer the hope of doing more good for our patients and their families, and addressing, at least in part, the recent emphasis on the needs and directions of relevant clinical research going forward.
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Conclusion
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